PDS Biotechnology Corporation
As of Oct 22, 2026, PDS Biotechnology is in Stage 1, the basing phase, now in week 3 (since Oct 8, 2026). It closed at $1.16, 27.5% below its 52-week high and above its 200-day average, which is rising.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is PDSB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PDSB among Biotechnology138th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …138 | PDSB | Stage 1 · wk 3 | 70 | +40.8% |
PDS Biotechnology: quick answers
What stage is PDS Biotechnology in?
As of Oct 22, 2026, PDS Biotechnology (PDSB) is in Stage 1, the basing phase. It entered Stage 1 on Oct 8, 2026 and is in week 3. What the four stages mean
Is PDS Biotechnology in an uptrend?
Not yet. PDS Biotechnology is in Stage 1, a base that can come before an uptrend. It trades 41.6% above its 200-day average, which is rising.
How far is PDS Biotechnology from its 52-week high?
PDS Biotechnology closed at $1.16 on Oct 22, 2026, 27.5% below its 52-week high of $1.60. Its 52-week low is $0.20.
How has PDS Biotechnology performed over the past year?
As of Oct 22, 2026, PDS Biotechnology is up 19.6% over the past year and up 39.3% so far in 2026.
Which sector and industry is PDS Biotechnology in?
PDS Biotechnology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.